Axsome Therapeutics Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
110.16
2.4
(2.23%)
Volume:
566,892
52 week range:
64.11 - 139.13
Market Cap:
5.424B
Company Description:
Axsome Therapeutics, Inc. engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the. treatment of smoking cessation. The firm was incorporated in 2012 and is based in New York, New York.